GlassScriptPhysician profile
Barbara J Opalka
NPI 1063404150
$6,512.65
in general payments reported to CMS, 2019-2025
43 companies · $729 in 2025
The $729 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $965 · 2020: $868 · 2021: $866 · 2022: $839 · 2023: $1,019 · 2024: $1,227 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,974.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $911.70 | 2021-2025 | |
| Lilly USA, LLC | $746.87 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $725.04 | 2019-2025 | Airsupra, Farxiga |
| Nestle Healthcare Nutrition INC. | $646.52 | 2022-2023 | |
| Pfizer INC. | $501.36 | 2019-2025 | |
| Allergan, INC. | $376.80 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $354.31 | 2024 | |
| Novo Nordisk INC | $205.50 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.98 | 2019-2023 | Tradjenta, Jardiance |
| Sanofi Pasteur INC. | $185.17 | 2019-2025 | |
| Arbor Pharmaceuticals, INC. | $147.77 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $133.65 | 2024-2025 | Voquezna |
| Amgen INC. | $123.70 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.37 | 2019-2021 | |
| Exact Sciences Corporation | $99.94 | 2023-2025 | Cologuard Collection Kit |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Opalka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.